Treating Metastatic Breast Cancer

Opinion
Video

Medical oncologists provide comprehensive insights on the standard-of-care treatment practices for patients with advanced/metastatic HR+ breast cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer

Roman Fabbricatore
October 14th 2025
Article

The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Experts discuss various treatment options for patients with HER2-positive breast cancer, and which would benefit the most based on their characteristics.

Analyzing Trials and Treatments in HER2+ Breast Cancer

Ariana Pelosci
October 11th 2025
Article

Experts discuss various treatment options for patients with HER2-positive breast cancer, and which would benefit the most based on their characteristics.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Oncotype DX 21-gene recurrence scores may help select certain patients who are suitable to omit radiotherapy for early-stage breast cancer.

Adjuvant Endocrine/Radiation Therapy May Limit Breast Cancer Recurrence

Russ Conroy
October 7th 2025
Article

Oncotype DX 21-gene recurrence scores may help select certain patients who are suitable to omit radiotherapy for early-stage breast cancer.

Cryoablation, when combined with adjuvant endocrine therapy, may offer a minimally invasive outpatient strategy in older patients with breast cancer.

Cryoablation Regimen Receives FDA Marketing Authorization for Breast Cancer

Roman Fabbricatore
October 7th 2025
Article

Cryoablation, when combined with adjuvant endocrine therapy, may offer a minimally invasive outpatient strategy in older patients with breast cancer.